Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

The study was also published today in the Journal of Thoracic Oncology, the official journal of IASLC.

In patients with stage II-IIIA disease, the eight-year overall survival rate was 74% with osimertinib compared with 58% with placebo, a 16-percentage-point difference. The hazard ratio for overall survival was 0.53 (95% CI, 0.38-0.75).

Across the overall stage IB-IIIA population, the eight-year overall survival rate was 79% with osimertinib versus 64% with placebo, a 15-percentage-point difference. The overall survival hazard ratio was 0.52 (95% CI, 0.39-0.71), and benefit was observed across predefined subgroups.

ADAURA is a global Phase III, double-blind, randomized trial that enrolled 682 patients with completely resected EGFR-mutated stage IB-IIIA NSCLC. Patients were randomized to receive once-daily osimertinib 80 mg or placebo for up to three years; adjuvant chemotherapy was permitted. All patients had already had the opportunity to complete three years of study treatment before this long-term exploratory analysis. The updated analysis extends earlier ADAURA findings demonstrating statistically significant disease-free survival and overall survival benefits with adjuvant osimertinib. Three years of adjuvant osimertinib is the standard of care in this setting.

These additional long-term findings further characterize the established survival benefit of adjuvant osimertinib for patients with resected EGFR-mutated stage IB-IIIA NSCLC, with or without adjuvant chemotherapy."

Roy Herbst, M.D., Phd, of Dartmouth Cancer Center, Lebanon, N.H.

This is the first study to establish the new paradigm that bringing the best targeted drugs to patients with earlier-stage disease can delay progression and improve survival. We have come such a long way in the 30 years since EGFR inhibitors were first introduced into clinical practice and this is great news for our patients.